COLUMBUS, Ohio – Dr. Charles Shapiro has been named to lead the breast cancer research program at the
Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer
Hospital and Richard J. Solove Research Institute (OSUCCC-James).
Shapiro will lead an interdisciplinary team of clinical and research
scientists whose sole focus is the study of breast cancer.
“By integrating clinical and translational research, our
research will lead to a greater understanding about the biology of breast
cancer, the development of new treatments for breast cancer, better methods for
early detection and how best to prevent it in the first place. Underlying and
at the center of everything we do in this great effort is women who have been
diagnosed with breast cancer and their families,” he said.
breast cancer research leader for a developing program within the OSUCCC, I
look forward to bringing together teams of basic, population and clinical
scientists to work together to achieve the latest in the prevention, detection
and treatment of breast cancer,” said Shapiro.
success in the breast cancer program is a two-way street, he said.
research to be the most successful, there must be very strong collaboration
between discoveries that are in made in the research lab and quickly tested in
women with breast cancer, and equally important are the observations made in
women with breast cancer that lead to questions that inform the next set of questions
that are tested in lab,” Shapiro said. He explained that Ohio State is uniquely
positioned to discovery transformative ways to prevent, detect and treat breast
cancers with an outstanding group of clinical scientists skilled to bring the
new discoveries to the clinic, one of the country’s highest rated National
Cancer Institute Comprehensive Cancer Center.
Shapiro’s efforts will focus on partnering with laboratory and
population scientists in three key areas of research including efforts to use
microRNAs to better understand the biology and classification of breast cancers,
developing new drugs for breast cancer treatment, and how best to treat the
breast cancer stromal tissue, which is the tissue that can exert anti-tumor
effects on breast cancer.
“These key areas are very strong within OSUCCC and developing
the means to enhance and expand these areas into early phase clinical trials is
one of my primary goals. As these teams of scientists learn more about breast
cancer, they will develop better methods for early detection and prevention,”
will lead efforts to increase the number of breast cancer clinical trials and
the number of patients on those trials as well as increasing the number of
funded investigators who specialize in breast cancer research.
“Dr. Shapiro will oversee an infrastructure to foster
breakthrough discoveries in breast cancer research that will allow the newest
and best treatments to reach patients as quickly as possible,” said Dr. Peter Shields, deputy
director of Ohio State’s Comprehensive Cancer Center – James Cancer Hospital
and Solove Research Institute.
Shapiro came to Ohio State in 1998 and is a professor of
internal medicine and also serves as director of breast medical oncology. He is
a nationally known clinical investigator whose research interests include the
development of novel treatments for breast cancer and treatment-related side
effects of breast cancer, in particular the side effects of adjuvant
chemotherapy in young women. He is currently overseeing major clinical trial
and laboratory research efforts to develop new therapies that are effective for
‘triple negative’ breast cancer.
serves as the vice chair of the Symptom Intervention Committee of
the Alliance Cooperative Group, is a member of the Alliance Breast Committee,
and a member of the NCI Symptom Management and Health-Related Quality of Life
Steering Committee. He has been named among “America’s Top Doctors for
Cancer,” “America’s Top Doctors” and “Best Doctors in America.”
State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital
and Richard J. Solove Research Institute strives to create a cancer-free
world by integrating scientific research with excellence in education and
patient-centered care, a strategy that leads to better methods of prevention,
detection and treatment. Ohio State is one of only 41 National Cancer Institute (NCI)-designated
Comprehensive Cancer Centers and one of only seven centers funded by the NCI to
conduct both phase I and phase II clinical trials. The NCI recently rated Ohio
State’s cancer program as “exceptional,” the highest rating given by NCI survey
teams. As the cancer program’s 210-bed adult patient-care component, The James
is a “Top Hospital” as named by the Leapfrog Group and one of the top 20 cancer
hospitals in the nation as ranked by U.S. News & World Report.
for a high-quality photo of Dr. Shapiro.
Contact: Gina Bericchia, Medical Center Public Affairs and Media Relations,